(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the US session.

The three biggest winners today are NASDAQ TEST STOCK, NewMarket, and Xenetic Biosciences.

The three biggest losers today are Align Technology, NeuroMetrix, and Western Digital.

Winners today

1. NASDAQ TEST STOCK (ZWZZT) – 30%

NASDAQ ended the session with NASDAQ TEST STOCK jumping 30% to $22.10 on Thursday, after five successive sessions in a row of losses. NASDAQ fell 1.76% to $12,595.61, following the last session’s downward trend on what was an all-around negative trend exchanging session today.

Yearly Top and Bottom Value

NASDAQ TEST STOCK’s stock is valued at $22.10 at 17:32 EST, under its 52-week low of $22.10.

More news about NASDAQ TEST STOCK.

2. NewMarket (NEU) – 10.46%

NewMarket Corporation, through its subsidiaries, primarily engages in the manufacture and sale of petroleum additives. The company offers lubricant additives for use in various vehicle and industrial applications, including engine oils, transmission fluids, off-road powertrain and hydraulic systems, gear oils, hydraulic oils, turbine oils, and other applications where metal-to-metal moving parts are utilized; engine oil additives designed for passenger cars, motorcycles, on and off-road heavy duty commercial equipment, locomotives, and engines in ocean-going vessels; driveline additives designed for products, such as transmission fluids, axle fluids, and off-road powertrain fluids; and industrial additives designed for products for industrial applications consisting of hydraulic fluids, grease, industrial gear fluids, and industrial specialty applications, such as turbine oils. It also provides fuel additives that are used to enhance the oil refining process and the performance of gasoline, diesel, biofuels, and other fuels to industry, government, original equipment manufacturers, and individual customers. In addition, the company engages in the marketing of antiknock compounds, as well as contracted manufacturing and services activities; and owns and manages a real property in Virginia. It operates in North America, Latin America, the Asia Pacific, Europe, the Middle East, Africa, and India. NewMarket Corporation was founded in 1887 and is headquartered in Richmond, Virginia.

NYSE ended the session with NewMarket jumping 10.46% to $484.17 on Thursday, following the last session’s downward trend. NYSE dropped 0.37% to $14,858.70, following the last session’s downward trend on what was a somewhat bearish trend trading session today.

Earnings Per Share

As for profitability, NewMarket has a trailing twelve months EPS of $35.94.

PE Ratio

NewMarket has a trailing twelve months price to earnings ratio of 13.47. Meaning, the purchaser of the share is investing $13.47 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 43.49%.

More news about NewMarket.

3. Xenetic Biosciences (XBIOW) – 10.42%

NASDAQ ended the session with Xenetic Biosciences jumping 10.42% to $7.42 on Thursday while NASDAQ dropped 1.76% to $12,595.61.

Moving Average

Xenetic Biosciences’s value is below its 50-day moving average of $7.87 and way above its 200-day moving average of $5.11.

More news about Xenetic Biosciences.

4. Exicure (XCUR) – 10.26%

Exicure, Inc., a clinical-stage biotechnology company, develops therapeutics for neurology, immuno-oncology, inflammatory diseases, and genetic disorders based on its proprietary spherical nucleic acid (SNA) technology. Its drug candidate includes AST-008 that is in a Phase 1b/2 clinical trials in patients with advanced solid tumors. The company is also developing XCUR-FXN, an SNA–based therapeutic candidate that is in preclinical trials for the treatment of Friedreich's ataxia; and XCUR17, an SNA that targets the messenger RNA (mRNA) encoding interleukin 17 receptor alpha. It has a collaboration, option, and license agreement with Allergan Pharmaceuticals International Limited to develop SNA-based treatments for hair loss disorders; and license and development agreement with DERMELIX, LLC to research, develop, and commercialize its technology for the treatment of netherton syndrome. The company was founded in 2011 and is based in Chicago, Illinois.

NASDAQ ended the session with Exicure jumping 10.26% to $0.63 on Thursday, following the last session’s upward trend. NASDAQ slid 1.76% to $12,595.61, following the last session’s downward trend on what was an all-around down trend exchanging session today.

Earnings Per Share

As for profitability, Exicure has a trailing twelve months EPS of $1.77.

PE Ratio

Exicure has a trailing twelve months price to earnings ratio of 0.36. Meaning, the purchaser of the share is investing $0.36 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 56.4%.

Sales Growth

Exicure’s sales growth is 6.1% for the ongoing quarter and 928% for the next.

Yearly Top and Bottom Value

Exicure’s stock is valued at $0.63 at 17:32 EST, way below its 52-week high of $1.78 and way higher than its 52-week low of $0.52.

More news about Exicure.

5. Flex (FLEX) – 10.19%

Flex Ltd. provides technology, supply chain, and manufacturing solutions in Asia, the Americas, and Europe. It operates through three segments: Flex Agility Solutions (FAS), Flex Reliability Solutions (FRS), and Nextracker. The FAS segment offers flexible supply and manufacturing system comprising communications, enterprise and cloud solution, which includes data, edge, and communications infrastructure; lifestyle solution including appliances, consumer packaging, floorcare, micro mobility, and audio; and consumer devices, such as mobile and high velocity consumer devices. Its FRS segment provides complex ramps with specialized production models and critical environments, which comprise automotive including next generation mobility, autonomous, connectivity, electrification, and smart technologies; health solutions, such as medical devices, medical equipment, and drug delivery; and industrial solutions including capital equipment, industrial devices, and renewables and grid edge. The Nextracker segment offers solar tracker and software solutions, which are used in utility-scale and ground-mounted distributed generation solar projects. In addition, it provides a broad array of services including design and engineering, component services, rapid prototyping, fulfillment, and circular economy solutions. The company was formerly known as Flextronics International Ltd. and changed its name to Flex Ltd. in September 2016. Flex Ltd. was founded in 1969 and is headquartered in Singapore.

NASDAQ ended the session with Flex jumping 10.19% to $25.58 on Thursday, following the last session’s downward trend. NASDAQ fell 1.76% to $12,595.61, following the last session’s downward trend on what was an all-around negative trend trading session today.

Earnings Per Share

As for profitability, Flex has a trailing twelve months EPS of $1.73.

PE Ratio

Flex has a trailing twelve months price to earnings ratio of 14.79. Meaning, the purchaser of the share is investing $14.79 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 21.06%.

Previous days news about Flex

• Flex (flex) surpasses Q2 earnings estimates. According to Zacks on Wednesday, 25 October, "While Flex has outperformed the market so far this year, the question that comes to investors’ minds is: what’s next for the stock?"

More news about Flex.

6. American Tower (AMT) – 8.55%

American Tower, one of the largest global REITs, is a leading independent owner, operator and developer of multitenant communications real estate with a portfolio of nearly 226,000 communications sites and a highly interconnected footprint of U.S. data center facilities.

NYSE ended the session with American Tower rising 8.55% to $175.78 on Thursday while NYSE fell 0.37% to $14,858.70.

American tower (amt) Q3 earnings: how key metrics compare to wall street estimatesFor the quarter ended September 2023, American Tower (AMT Quick QuoteAMT – Free Report) reported revenue of $2.82 billion, up 5.5% over the same period last year. , Here is how American Tower performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

Earnings Per Share

As for profitability, American Tower has a trailing twelve months EPS of $2.06.

PE Ratio

American Tower has a trailing twelve months price to earnings ratio of 85.33. Meaning, the purchaser of the share is investing $85.33 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 7.74%.

More news about American Tower.

7. ImmunoGen (IMGN) – 7.3%

ImmunoGen, Inc., a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) for cancer patients. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), for the treatment of platinum-resistant ovarian cancer; and a cell-surface protein expressed in various epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers, as well as Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti-FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.

NASDAQ ended the session with ImmunoGen jumping 7.3% to $14.69 on Thursday while NASDAQ slid 1.76% to $12,595.61.

Earnings Per Share

As for profitability, ImmunoGen has a trailing twelve months EPS of $-0.71.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -49.15%.

More news about ImmunoGen.

8. FMC Technologies (FTI) – 7.07%

TechnipFMC plc engages in the oil and gas projects, technologies, and systems and services businesses in Europe, Central Asia, North and Latin America, the Asia Pacific, Africa, and the Middle East. The Subsea segment engages in the design, engineering, procurement, manufacturing, fabrication, installation, and life of field services for subsea systems, subsea field infrastructure, and subsea pipe systems used in oil and gas production and transportation. It provides subsea production and flexible pipe; subsea umbilicals, risers, and flowlines; vessels; and Subsea Studio for optimizing the development, execution, and operation of current and future subsea fields. This segment also offers well and asset services. The Surface Technologies segment designs, manufactures, and services products and systems used in land and shallow water exploration and production of crude oil and natural gas. This segment offers surface wellheads and production trees systems; iComplete, a pressure control system; fracturing tree and manifold systems; pressure pumping; safety and integrity systems, multiphase meter modules, in-line separation and processing systems, and standard pumps; well control and integrity systems, flowback and well testing services; skid systems; digital systems; and flow measurement and automation solutions. It also offers planning, testing and installation, commissioning, operations, replacement and upgrade, maintenance, storage, preservation, intervention, integrity, decommissioning, and abandonment; and supplies flexible lines and flowline products and services. TechnipFMC plc has a strategic alliance with Talos Energy Inc. to develop carbon transportation and storage services. The company was founded in 1884 and is based in Newcastle Upon Tyne, the United Kingdom.

NYSE ended the session with FMC Technologies jumping 7.07% to $21.34 on Thursday while NYSE dropped 0.37% to $14,858.70.

FMC technologies (fti) Q3 earnings: how key metrics compare to wall street estimatesHere is how FMC Technologies performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

Earnings Per Share

As for profitability, FMC Technologies has a trailing twelve months EPS of $-0.25.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -3.04%.

Volume

Today’s last reported volume for FMC Technologies is 7161130 which is 19.97% above its average volume of 5969060.

Moving Average

FMC Technologies’s worth is above its 50-day moving average of $19.61 and way higher than its 200-day moving average of $15.69.

Growth Estimates Quarters

The company’s growth estimates for the current quarter and the next is 533.3% and 340%, respectively.

More news about FMC Technologies.

9. Y-mAbs Therapeutics (YMAB) – 6.79%

Y-mAbs Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody-based therapeutic products for the treatment cancer in the United States. The company develops naxitamab that is in Phase 2 clinical trial for the treatment of pediatric patients with relapsed steosarcoma or refractory, and high-risk neuroblastoma, as well as other GD2 positive tumors; and GD2-GD3 Vaccine which is in Phase 2 clinical trial for the treatment of high-risk neuroblastoma. It is developing omburtamab that is in Phase 2 clinical trial for the treatment of desmoplastic small round cell tumors; in Phase 1 clinical trial for the treatment of diffuse intrinsic pontine glioma, as well as for the treatment of pediatric patients with central nervous system and leptomeningeal metastases; The company also engages in the development of huB7-H3 product candidate for the treatment of B7-H3 positive adult solid tumors; and pre clinical development of huCD33 BsAb product candidate for the treatment of huCD33 positive hermatological cancers. The company has a license and research collaboration agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize antibody constructs based on the SADA-BiDE pre-targeted radioimmunotherapy platform. Y-mAbs Therapeutics, Inc. was founded in 2015 and is headquartered in New York, New York.

NASDAQ ended the session with Y-mAbs Therapeutics rising 6.79% to $5.35 on Thursday, following the last session’s upward trend. NASDAQ slid 1.76% to $12,595.61, following the last session’s downward trend on what was an all-around bearish trend trading session today.

Earnings Per Share

As for profitability, Y-mAbs Therapeutics has a trailing twelve months EPS of $-0.9.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -33.09%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 92.2%, now sitting on 84.99M for the twelve trailing months.

More news about Y-mAbs Therapeutics.

10. First Citizens BancShares (FCNCA) – 6.4%

First Citizens BancShares, Inc. operates as the holding company for First-Citizens Bank & Trust Company that provides retail and commercial banking services to individuals, businesses, and professionals. The company's deposit products include checking, savings, money market, and time deposit accounts. Its loan product portfolio comprises commercial construction and mortgage; and commercial and industrial leases, as well as small business administration paycheck protection program loans. In addition, the company offers consumer loans, such as residential and revolving mortgage, construction and land development, consumer auto, and other consumer loans. Further, it provides wealth management services, including annuities, discount brokerage services, and third-party mutual funds, as well as investment management and advisory services. The company provides its products and services through its branch network. First Citizens BancShares, Inc. was founded in 1898 and is headquartered in Raleigh, North Carolina.

NASDAQ ended the session with First Citizens BancShares jumping 6.4% to $1,384.98 on Thursday while NASDAQ fell 1.76% to $12,595.61.

Earnings Per Share

As for profitability, First Citizens BancShares has a trailing twelve months EPS of $735.44.

PE Ratio

First Citizens BancShares has a trailing twelve months price to earnings ratio of 1.88. Meaning, the purchaser of the share is investing $1.88 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 70.84%.

Yearly Top and Bottom Value

First Citizens BancShares’s stock is valued at $1,384.98 at 17:32 EST, under its 52-week high of $1,512.07 and way higher than its 52-week low of $505.84.

Growth Estimates Quarters

The company’s growth estimates for the current quarter and the next is 149% and 174.7%, respectively.

Revenue Growth

Year-on-year quarterly revenue growth grew by 123%, now sitting on 5.23B for the twelve trailing months.

More news about First Citizens BancShares.

Losers Today

1. Align Technology (ALGN) – -25.06%

Align Technology, Inc. designs, manufactures, and markets Invisalign clear aligners, and iTero intraoral scanners and services for orthodontists and general practitioner dentists in the United States, Switzerland, China, and internationally. It operates in two segments, Clear Aligner; and Imaging Systems and CAD/CAM Services (Systems and Services). The Clear Aligner segment offers comprehensive products, including Invisalign comprehensive package that addresses the orthodontic needs of teenage patients, such as mandibular advancement, compliance indicators, and compensation for tooth eruption; and Invisalign First Phase I and Invisalign First Comprehensive Phase 2 package for younger patients generally between the ages of seven and ten years, which is a mixture of primary/baby and permanent teeth. This segment's non-comprehensive products comprise Invisalign moderate, lite and express packages, and Invisalign go and Invisalign Go Plus; and non-case products that include retention products, Invisalign training, and adjusting tools used by dental professionals during the course of treatment. The Systems and Services segment offers iTero intraoral scanning system, a single hardware platform with software options for restorative or orthodontic procedures; restorative software for general practitioner dentists, prosthodontists, periodontists, and oral surgeons; and software for orthodontists for digital records storage, orthodontic diagnosis, and for the fabrication of printed models and retainers. This segment also provides Invisalign outcome simulator, a chair-side and cloud-based application for the iTero scanner; Invisalign progress assessment tool; and TimeLapse technology, which allows doctors or practitioners to compare a patient's historic 3D scans to the present-day scan, as well as subscription software, disposables, rentals, leases, and pay per scan services Align Technology, Inc. was incorporated in 1997 and is headquartered in Tempe, Arizona.

NASDAQ ended the session with Align Technology dropping 25.06% to $190.12 on Thursday, after five sequential sessions in a row of losses. NASDAQ slid 1.76% to $12,595.61, following the last session’s downward trend on what was an all-around negative trend exchanging session today.

Earnings Per Share

As for profitability, Align Technology has a trailing twelve months EPS of $4.06.

PE Ratio

Align Technology has a trailing twelve months price to earnings ratio of 46.83. Meaning, the purchaser of the share is investing $46.83 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.68%.

Moving Average

Align Technology’s worth is way under its 50-day moving average of $320.91 and way below its 200-day moving average of $317.79.

Revenue Growth

Year-on-year quarterly revenue growth grew by 3.4%, now sitting on 3.74B for the twelve trailing months.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Align Technology’s EBITDA is 153.01.

Volume

Today’s last reported volume for Align Technology is 3277670 which is 380.11% above its average volume of 682690.

Previous days news about Align Technology

• Align technology (algn) lags Q3 earnings and revenue estimates. According to Zacks on Wednesday, 25 October, "While Align Technology has outperformed the market so far this year, the question that comes to investors’ minds is: what’s next for the stock?"
• Compared to estimates, align technology (algn) Q3 earnings: A look at key metrics. According to Zacks on Wednesday, 25 October, "For the quarter ended September 2023, Align Technology (ALGN Quick QuoteALGN – Free Report) reported revenue of $960.21 million, up 7.9% over the same period last year. ", "Here is how Align Technology performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:"

More news about Align Technology.

2. NeuroMetrix (NURO) – -20.61%

NeuroMetrix, Inc., a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, China, the Middle East, and Mexico. Its primary marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system, a platform for the performance of nerve conduction studies. The company offers its products to managed care organizations, endocrinologists, podiatrists, and primary care physicians; occupational health, primary care, internal medicine, orthopedic, and hand surgeons; and pain medicine physicians, neurologists, physical medicine and rehabilitation physicians, and neurosurgeons. NeuroMetrix, Inc. was incorporated in 1996 and is headquartered in Woburn, Massachusetts.

NASDAQ ended the session with NeuroMetrix dropping 20.61% to $0.53 on Thursday while NASDAQ fell 1.76% to $12,595.61.

Earnings Per Share

As for profitability, NeuroMetrix has a trailing twelve months EPS of $-0.72.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -24.14%.

More news about NeuroMetrix.

3. Western Digital (WDC) – -10.95%

Western Digital Corporation develops, manufactures, and sells data storage devices and solutions in the United States, China, Hong Kong, Europe, the Middle East, Africa, rest of Asia, and internationally. It offers client devices, including hard disk drives (HDDs) and solid state drives (SSDs) for desktop and notebook personal computers (PCs), gaming consoles, and set top boxes; and flash-based embedded storage products for mobile phones, tablets, notebook PCs, and other portable and wearable devices, as well as automotive, Internet of Things, industrial, and connected home applications. The company also provides enterprise HDDs; enterprise SSDs consisting of flash-based SSDs and software solutions for use in enterprise servers, online transactions, data analysis, and other enterprise applications; and data storage platforms. In addition, it offers external HDD storage products in mobile and desktop form; client portable SSDs; removable cards that are used in consumer devices comprising mobile phones, tablets, imaging systems, and cameras and smart video systems; universal serial bus flash drives for use in the computing and consumer markets; and wireless drive products used in-field backup of created content, as well as wireless streaming of high-definition movies, photos, music, and documents to tablets, smartphones, and PCs. The company sells its products under the Western Digital, SanDisk, and WD brands to original equipment manufacturers, distributors, dealers, resellers, and retailers. Western Digital Corporation was founded in 1970 and is headquartered in San Jose, California.

NASDAQ ended the session with Western Digital falling 10.95% to $37.56 on Thursday, following the last session’s downward trend. NASDAQ dropped 1.76% to $12,595.61, following the last session’s downward trend on what was an all-around bearish trend trading session today.

Earnings Per Share

As for profitability, Western Digital has a trailing twelve months EPS of $-5.44.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -14.25%.

More news about Western Digital.

4. Hasbro (HAS) – -10.45%

Hasbro, Inc., together with its subsidiaries, operates as a play and entertainment company in the United States and internationally. The company operates through Consumer Products, Wizards of the Coast and Digital Gaming, and Entertainment segments. The Consumer Products segment engages in the sourcing, marketing, and sale of toy and game products. This segment also promotes its brands through the out-licensing of trademarks, characters, and other brand and intellectual property rights to third parties through the sale of branded consumer products, such as toys and apparels. Its toys and games include action figures, arts and crafts and creative play products, fashion and other dolls, play sets, preschool toys, plush products, sports action blasters and accessories, vehicles and toy-related specialty products, games, and other consumer products; and licensed products, such as apparels, publishing products, home goods and electronics, and toy products. The Wizards of the Coast and Digital Gaming segment engages in the promotion of its brands through the development of trading card, role-playing, and digital game experiences based on Hasbro and Wizards of the Coast games. The Entertainment segment engages in the development, acquisition, production, distribution, and sale of world-class entertainment content, including film, scripted and unscripted television, family programming, digital content, and live entertainment. The company sells its products to retailers, distributors, wholesalers, discount stores, drug stores, mail order houses, catalog stores, department stores, and other traditional retailers, as well as ecommerce retailers; and directly to customer through Hasbro PULSE e-commerce website. The company was founded in 1923 and is headquartered in Pawtucket, Rhode Island.

NASDAQ ended the session with Hasbro sliding 10.45% to $49.03 on Thursday, following the last session’s downward trend. NASDAQ fell 1.76% to $12,595.61, following the last session’s downward trend on what was an all-around negative trend trading session today.

: hasbro stock sinks toward a 7-month low after profit and revenue miss, slashed outlookShares of Hasbro Inc. sank 8.7% toward a seven-month low in premarket trading Thursday, after the toy maker missed third-quarter profit and revenue expectations and slashed its full-year outlook, citing a softer toy outlook in consumer products.

Compared to estimates, hasbro (has) Q3 earnings: A look at key metricsHere is how Hasbro performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

Why toymaker hasbro is having its worst stock-market month since the ’80sShares of Hasbro Inc. got rocked Thursday, making investors suffer through the worst month in four decades, as a weakening toy market led the company to report disappointing third-quarter results.

Earnings Per Share

As for profitability, Hasbro has a trailing twelve months EPS of $-1.85.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -9.34%.

Previous days news about Hasbro

• Hasbro (has) to report Q3 earnings: what's in the offing?. According to Zacks on Tuesday, 24 October, "Backed by a global retail network and investments in new channels, Hasbro continues to witness solid growth in its e-commerce revenues.", "Our proven model doesn’t conclusively predict an earnings beat for Hasbro this time around. "

More news about Hasbro.

5. West Pharmaceutical (WST) – -10.02%

West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. The company serves pharmaceutical, diagnostic, and medical device companies. It distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. The company was incorporated in 1923 and is headquartered in Exton, Pennsylvania.

NYSE ended the session with West Pharmaceutical dropping 10.02% to $322.14 on Thursday, after three consecutive sessions in a row of losses. NYSE fell 0.37% to $14,858.70, following the last session’s downward trend on what was a somewhat bearish trend trading session today.

Here's what key metrics tell us about west pharmaceutical (wst) Q3 earningsHere is how West Pharmaceutical performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

Earnings Per Share

As for profitability, West Pharmaceutical has a trailing twelve months EPS of $6.87.

PE Ratio

West Pharmaceutical has a trailing twelve months price to earnings ratio of 46.89. Meaning, the purchaser of the share is investing $46.89 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 20.06%.

Earnings Before Interest, Taxes, Depreciation, and Amortization

West Pharmaceutical’s EBITDA is 125.53.

More news about West Pharmaceutical.

6. Riot Blockchain (RIOT) – -9.09%

Riot Platforms, Inc., together with its subsidiaries, operates as a bitcoin mining company in North America. It operates through Bitcoin Mining, Data Center Hosting, and Engineering segments. The company also provides co-location services for institutional-scale bitcoin mining companies; and critical infrastructure and workforce for institutional-scale miners to deploy and operate their miners. In addition, it engages in the design and manufacturing of power distribution equipment and custom engineered electrical products; electricity distribution product design, manufacture, and installation services primarily focused on large-scale commercial and governmental customers, as well as a range of markets, including data center, power generation, utility, water, industrial, and alternative energy; operation of data centers; and maintenance/management of computing capacity. The company was formerly known as Riot Blockchain, Inc. Riot Platforms, Inc. was incorporated in 1998 and is based in Castle Rock, Colorado.

NASDAQ ended the session with Riot Blockchain dropping 9.09% to $9.60 on Thursday, following the last session’s downward trend. NASDAQ fell 1.76% to $12,595.61, following the last session’s downward trend on what was an all-around bearish trend exchanging session today.

Earnings Per Share

As for profitability, Riot Blockchain has a trailing twelve months EPS of $-1.6.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -21.82%.

Growth Estimates Quarters

The company’s growth estimates for the current quarter and the next is 8.3% and 72.2%, respectively.

More news about Riot Blockchain.

7. Allison Transmission Holdings (ALSN) – -8.16%

Allison Transmission Holdings, Inc., together with its subsidiaries, designs, manufactures, and sells commercial and defense fully-automatic transmissions for medium- and heavy-duty commercial vehicles, and medium- and heavy-tactical U.S. defense vehicles worldwide. It offers 12 transmission product lines for various applications, including distribution, refuse, construction, fire, and emergency on-highway trucks; school and transit buses; motor homes; energy, mining, and construction off-highway vehicles and equipment; and wheeled and tracked defense vehicles. The company markets its transmissions under Allison Transmission brand name; and remanufactured transmissions under ReTran brand name. It also sells branded replacement parts, support equipment, aluminum die cast components, and other products necessary to service the installed base of vehicles utilizing its transmissions, as well as defense kits, engineering services, and extended transmission coverage services to various original equipment manufacturers, distributors, and the U.S. government. The company serves customers through an independent network of approximately 1,500 independent distributor and dealer locations. The company was formerly known as Clutch Holdings, Inc. Allison Transmission Holdings, Inc. was founded in 1915 and is headquartered in Indianapolis, Indiana.

NYSE ended the session with Allison Transmission Holdings falling 8.16% to $52.53 on Thursday while NYSE dropped 0.37% to $14,858.70.

Earnings Per Share

As for profitability, Allison Transmission Holdings has a trailing twelve months EPS of $6.72.

PE Ratio

Allison Transmission Holdings has a trailing twelve months price to earnings ratio of 7.82. Meaning, the purchaser of the share is investing $7.82 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 66.19%.

Yearly Top and Bottom Value

Allison Transmission Holdings’s stock is valued at $52.53 at 17:32 EST, way below its 52-week high of $61.53 and way higher than its 52-week low of $39.53.

Volume

Today’s last reported volume for Allison Transmission Holdings is 450294 which is 23.92% below its average volume of 591875.

More news about Allison Transmission Holdings.

8. Westwater Resources (WWR) – -8.09%

Westwater Resources, Inc. operates as a diversified energy materials development company. It primarily explores for lithium, graphite, uranium, and Vanadium deposits. The company's principal project is the Coosa graphite project covering an area of approximately 41,965 acres situated in east-central Alabama. It also holds interest in lithium projects, which include Columbus Basin project covers an area of approximately 14,200 acres comprise of 2 blocks of unpatented placer claims located in western Nevada; and the Sal Rica Project covers an area of approximately 13,260 acres situated in the northwestern Utah. It addition, the company holds interests in various uranium projects, including 188,700 acres in the west-central part of the New Mexico; and Texas. The company was formerly known as Uranium Resources, Inc. and changed its name to Westwater Resources, Inc. in August 2017. Westwater Resources, Inc. was founded in 1977 and is based in Centennial, Colorado.

NASDAQ ended the session with Westwater Resources sliding 8.09% to $0.62 on Thursday while NASDAQ fell 1.76% to $12,595.61.

Earnings Per Share

As for profitability, Westwater Resources has a trailing twelve months EPS of $-0.23.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -7.87%.

More news about Westwater Resources.

9. Arista Networks (ANET) – -8.07%

Arista Networks, Inc. develops, markets, and sells cloud networking solutions in the Americas, Europe, the Middle East, Africa, and the Asia-Pacific. The company's cloud networking solutions consist of extensible operating systems, a set of network applications, as well as gigabit Ethernet switching and routing platforms. It also provides post contract customer support services, such as technical support, hardware repair and parts replacement beyond standard warranty, bug fix, patch, and upgrade services. The company serves a range of industries comprising internet companies, service providers, financial services organizations, government agencies, media and entertainment companies, telecommunication service providers, and others. It markets and sells its products through distributors, system integrators, value-added resellers, and original equipment manufacturer partners, as well as through its direct sales force. The company was formerly known as Arastra, Inc. and changed its name to Arista Networks, Inc. in October 2008. Arista Networks, Inc. was incorporated in 2004 and is headquartered in Santa Clara, California.

NYSE ended the session with Arista Networks sliding 8.07% to $171.07 on Thursday, following the last session’s downward trend. NYSE fell 0.37% to $14,858.70, following the last session’s downward trend on what was a somewhat negative trend trading session today.

Earnings Per Share

As for profitability, Arista Networks has a trailing twelve months EPS of $5.42.

PE Ratio

Arista Networks has a trailing twelve months price to earnings ratio of 31.56. Meaning, the purchaser of the share is investing $31.56 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 34.66%.

More news about Arista Networks.

10. X4 Pharmaceuticals (XFOR) – -7.96%

X4 Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for the treatment of primary immune-deficiencies and cancer. Its lead drug candidate is mavorixafor (X4P-001), an oral small molecule antagonist of chemokine receptor CXCR4, which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; Phase Ib clinical trial to treat severe congenital neutropenia and Waldenström macroglobulinemia; and Phase IIa clinical trial for the treatment of clear cell renal cell carcinoma. The company is also developing X4P-002 for the treatment of glioblastoma multiforme; and X4P-003 to treat primary immune-deficiencies. It has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company was formerly known as Arsanis, Inc. and changed its name to X4 Pharmaceuticals, Inc. in March 2019. X4 Pharmaceuticals, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.

NASDAQ ended the session with X4 Pharmaceuticals dropping 7.96% to $0.76 on Thursday, after five consecutive sessions in a row of losses. NASDAQ fell 1.76% to $12,595.61, following the last session’s downward trend on what was an all-around down trend exchanging session today.

Earnings Per Share

As for profitability, X4 Pharmaceuticals has a trailing twelve months EPS of $-0.72.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -267.24%.

Earnings Before Interest, Taxes, Depreciation, and Amortization

X4 Pharmaceuticals’s EBITDA is -10.17.

More news about X4 Pharmaceuticals.

Stay up to date with our winners and losers daily report